Wellbutrin and Glaucoma: Safety Considerations
Wellbutrin (bupropion) is generally safe in patients with open-angle glaucoma but carries a significant risk of precipitating acute angle-closure in susceptible individuals, particularly those under 50 years of age. 1
Type of Glaucoma Matters Critically
Open-Angle Glaucoma: Generally Safe
- Patients with established open-angle glaucoma can safely use bupropion, as the FDA label explicitly states that "open-angle glaucoma is not a risk factor for angle-closure glaucoma." 1
- Multiple large-scale studies demonstrate that bupropion may actually be protective against open-angle glaucoma development, with extended use (24-48 months) associated with a 21% reduced risk. 2
- Each additional month of bupropion use was associated with a 0.6% reduced risk of developing open-angle glaucoma in a cohort of over 638,000 patients. 2
- Population-based data from NHANES showed that bupropion use for more than 1 year was associated with significantly decreased odds of glaucoma (adjusted OR=0.1,95% CI 0.01-0.81). 3
Narrow-Angle or Angle-Closure Risk: Significant Concern
- Bupropion can cause mild pupillary dilation, which in susceptible individuals can trigger acute angle-closure glaucoma. 1
- The risk of angle-closure glaucoma is nearly doubled in patients under 50 years taking bupropion (adjusted rate ratio 1.98,95% CI 1.02-3.84). 4
- A case report documented bilateral acute angle-closure crisis with uveal effusions directly attributed to bupropion, requiring immediate discontinuation and aggressive treatment. 5
Clinical Decision Algorithm
Step 1: Determine Glaucoma Type
- If the patient has documented open-angle glaucoma with an open anterior chamber angle on gonioscopy, bupropion can be prescribed safely. 6, 1
- If glaucoma type is unknown or the patient has never had gonioscopy, proceed with caution. 1
Step 2: Assess Angle-Closure Risk
- The FDA label emphasizes that "pre-existing glaucoma is almost always open-angle glaucoma because angle-closure glaucoma, when diagnosed, can be treated definitively with iridectomy." 1
- Patients without prior gonioscopy should be considered at unknown risk for anatomically narrow angles. 1
- Age under 50 years significantly increases angle-closure risk with bupropion. 4
Step 3: Risk Mitigation Strategy
- For patients with unknown angle anatomy or risk factors for narrow angles (hyperopia, family history, Asian ethnicity), consider ophthalmology referral for gonioscopic examination before initiating bupropion. 1
- The FDA recommends that "patients may wish to be examined to determine whether they are susceptible to angle closure, and have a prophylactic procedure (e.g., iridectomy), if they are susceptible." 1
- If bupropion is started without prior examination, counsel patients to seek immediate care for symptoms of acute angle-closure: sudden eye pain, headache, blurred vision, halos around lights, or nausea/vomiting. 5
Important Caveats
Medication Review is Critical
- A thorough medication review is essential when evaluating bilateral angle-closure presentations, as bupropion-induced cases may be missed without careful history. 5
- Bupropion is marketed under multiple brand names (Wellbutrin, Zyban, Aplenzin) and should not be combined with other bupropion-containing products. 1
Monitoring Considerations
- Patients with open-angle glaucoma on bupropion do not require special IOP monitoring beyond their standard glaucoma care. 6, 2
- If acute angle-closure occurs, immediate discontinuation of bupropion is mandatory, along with urgent ophthalmologic intervention including atropine, corticosteroids, and IOP-lowering medications. 5
Comparative Context
- Unlike other antidepressants (SSRIs, tricyclics), bupropion has a unique pharmacologic profile with potential neuroprotective effects via TNF-alpha modulation in open-angle glaucoma. 2, 7
- The angle-closure risk with bupropion (RR 1.98 in patients <50) is lower than with topiramate (RR 5.30), but still clinically significant. 4